DataSet Record GDS2298: Expression Profiles Data Analysis Tools Sample Subsets
Title: Gefitinib effect on various non-small cell lung cancer cell lines (HG-U133B)
Cluster AnalysisGDS2298 Cluster Image
Summary: Analysis of baseline non-small cell lung cancer (NSCLC) cell lines with a broad range of sensitivity to the anticancer drug gefitinib. Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Results used to define a gene expression signature of gefitinib sensitivity.
Organism: Homo sapiens
Platform: GPL97: [HG-U133B] Affymetrix Human Genome U133B Array
  • Coldren CD, Helfrich BA, Witta SE, Sugita M et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 2006 Aug;4(8):521-8. PMID: 16877703
  • Barthel BL, Zhang Z, Rudnicki DL, Coldren CD et al. Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine. J Med Chem 2009 Dec 10;52(23):7678-88. PMID: 19634903
Reference Series: GSE4342 Sample count: 18
Value type: transformed count Series published: 2006/08/31